Washington University School of Medicine
This trial tests the effects of two versions of RiskProfile, a clinically-informed and a genetically-informed version of a patient-specific risk feedback tool, in comparison to usual care, on lung cancer screening and tobacco treatment. The trial assesses the multilevel effects of these precision risk feedback tools on the likelihood of clinicians to order lung cancer screening and tobacco treatment and of their patients to utilize these cancer prevention interventions.
The overarching goal of this study is to test the impact of a precision risk feedback tool aiming to address gaps in clinician and patient uptake of lung cancer screening and tobacco treatment. This study builds on evidence that (1) clinical and genetic factors may inform precision risk on lung cancer and smoking cessation and (2) increasingly high demand for personal genetic risk in particular may signal its potential to activate behavior change. The multi-level precision prevention intervention to be tested--RiskProfile-- provides the opportunity to present personalized clinical and genetic…
Inclusion Criteria: CLINICIANS: \- Primary care clinician with active caseload in participating clinics PATIENTS: * Patient of participating primary care clinician * Lung cancer screening naïve * Between 50 to 80 years of age, inclusive * Current or former smokers * Pack years ≥ 20 * English-speaking Exclusion Criteria: PATIENTS: * Lung cancer diagnosis * Current order placed for lung cancer screening
Usual care incorporates guideline awareness and brief advice.
RiskProfile-Clin incorporates standard brief advice and guideline awareness plus specific patient risk feedback using clinical factors.
RiskProfile-Gen incorporates standard brief advice and guideline awareness plus specific patient risk feedback using clinical factors and genetic factors.
Arctuva estimate
Actual pay is set by the research site.
Verify or correct the compensation shown for this listing.